Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/06/26
BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/06/26
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ETPRNewsWire • 07/30/26
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 07/27/26
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU SyndromePRNewsWire • 07/27/26
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With AchondroplasiaPRNewsWire • 07/13/26
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026PRNewsWire • 06/16/26
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/03/26
BioMarin's Voxzogo Meets Goal in Late-Stage Study for HypochondroplasiaZacks Investment Research • 05/21/26
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with HypochondroplasiaPRNewsWire • 05/20/26
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 DeficiencyPRNewsWire • 05/18/26
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance RaisedZacks Investment Research • 05/05/26
Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 05/05/26